
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$11.40
−US$0.12 · -1.04%
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
前收盘价
US$11.40
−US$0.12 · -1.04%
盘前
US$11.40
US$0.00 · 0.00%
10月13日 6:09 ET
盘中时间采用ET。市场数据可能有所延迟。
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
日内区间
当前US$11.40
52周区间
当前US$11.40
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
48
合理估值
情绪
43
多空交织
风险
33
中等风险
动量
54
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
日内区间
当前US$11.40
52周区间
当前US$11.40
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 3.2亿 USD | 2.92亿 USD | 3.04亿 USD | 3.39亿 USD | 3.16亿 USD |
| 销货成本 | 1.45亿 USD | 1.35亿 USD | 1.49亿 USD | 1.65亿 USD | 1.5亿 USD |
| 毛利 | 1.75亿 USD | 1.58亿 USD | 1.55亿 USD | 1.74亿 USD | 1.66亿 USD |
| 研究与开发 | 2944.7万 USD | 2622.2万 USD | 3151.2万 USD | 2988.3万 USD | 3073.9万 USD |
| 销售、一般及管理费用 | 1.57亿 USD | 1.45亿 USD | 1.44亿 USD | 1.44亿 USD | 1.34亿 USD |
| 营业费用 | 2.15亿 USD | 1.98亿 USD | 3.47亿 USD | 2.25亿 USD | 1.94亿 USD |
| 利息收入 | — | 97.8万 USD | 161.4万 USD | — | — |
| 利息支出 | 29.9万 USD | — | — | 270.2万 USD | 68.8万 USD |
| 折旧和摊销 | 2295.5万 USD | 2580万 USD | 2771.2万 USD | 3087.3万 USD | 2934.9万 USD |
| 营业利润 | −3992.7万 USD | −3995.4万 USD | −1.92亿 USD | −5118.1万 USD | −2847.1万 USD |
| 净利润 | −3674.2万 USD | −3399.3万 USD | −1.84亿 USD | −5244.2万 USD | −2654.7万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$19.50
上涨空间 71.05%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1892.42万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1116.72万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF782.18万0.01%954亿 USD0.05%US$233.52-0.63%
Dimensional - US Small Cap ETFDFAS370.28万0.01%338.04亿 USD0.31%US$78.17-0.23%
Vanguard Russell 2000 ETFVTWO344.76万0.02%180亿 USD0.06%US$112.27-0.35%
Dimensional - US Core Equity 2 ETFDFAC225.97万0.00%885.59亿 USD0.21%US$45.31-0.04%
Schwab U.S. Small-Cap ETFSCHA223.67万0.01%217.13亿 USD0.03%US$32.66-0.40%
iShares U.S. Medical Devices ETFIHI214.56万0.06%35.74亿 USD0.37%US$52.79+2.03%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
Vanguard Russell 2000 ETFVTWO
Dimensional - US Core Equity 2 ETFDFAC
Schwab U.S. Small-Cap ETFSCHA
iShares U.S. Medical Devices ETFIHIAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。